Skip to main content
main-content

Zeitschrift

Targeted Oncology

Targeted Oncology OnlineFirst articles

19.09.2018 | Original Research Article

Immediate Progressive Disease in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab: a Multi-Institution Retrospective Study

The immune checkpoint inhibitor (ICI) nivolumab has been approved for previously treated patients with metastatic renal cell carcinoma (mRCC), based on the findings of the pivotal phase III CheckMate 025 trial [ 1 ], which demonstrated that …

18.09.2018 | Review Article

Targeting Toll-Like Receptors for Cancer Therapy

The immune system encompasses a broad array of defense mechanisms against foreign threats, including invading pathogens and transformed neoplastic cells. Toll-like receptors (TLRs) are critically involved in innate immunity, serving as pattern …

14.09.2018 | Original Research Article

Characteristics and Response to Crizotinib in ALK-Rearranged, Advanced Non-Adenocarcinoma, Non-Small Cell Lung Cancer (NA-NSCLC) Patients: a Retrospective Study and Literature Review

Fusion proteins involving anaplastic lymphoma kinase (ALK) define a unique molecular subtype of non-small cell lung cancer (NSCLC) and can be detected in 5–7% of unselected NSCLC patients, especially in adenocarcinoma and younger patients [ 1 , 2 …

30.08.2018 | Original Research Article

Comparison Between Prognostic Classifications in De Novo Metastatic Hormone Sensitive Prostate Cancer

Prostate cancer (PC) is the most frequently diagnosed solid tumour among men and the third leading cause of cancer-related deaths [ 1 , 2 ]. In Europe, today only 4% of newly diagnosed patients present with metastatic disease [ 3 ]. De novo hormone …

24.08.2018 | Review Article

Targeted Therapies in the Treatment of Sarcomas

About 50% of sarcomas have specific pathology-defining molecular alterations including mutations, fusion genes, and gene amplifications. Some of these alterations appear to be oncogenic drivers, and a subset can be utilized as targets for standard …

Aktuelle Ausgaben

Weitere Informationen

Neu im Fachgebiet Onkologie

 

 

 
 

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise